Nootropic peptide stacks: separating signal from TikTok hype

What did @travis.mind actually say?

Travis reviewed what he calls "Clavicular's Nootropic Stack," rating it 5 out of 10. The stack includes caffeine, 7.5mg Adderall IR, Noopept paired with a choline source, and Cerebrolysin. He dismissed Noopept as "pretty garbage" and potentially neurotoxic, suggested replacing it with Piracetam, and framed Cerebrolysin as a neurogenesis tool useful for recovering from "heavy stimulant abuse and sleep deprivation." He also argued that immediate-release Adderall is "much more superior" to extended-release for avoiding sleep disruption and health risks.

The transcript is messy, clearly auto-captioned with garbled sections, so some claims are hard to pin down exactly. What is clear: this is a TikTok creator casually discussing Schedule II controlled substances and injectable peptides as if they are supplement stack decisions. That framing deserves scrutiny before anything else.

Does the science back this up?

Some of it does, some of it is oversimplified, and at least one claim is backwards. Caffeine blocking adenosine receptors is textbook pharmacology (Fredholm et al., 1999, Pharmacological Reviews). The claim that Adderall IR causes fewer sleep disturbances than XR has some basis: peak plasma timing matters, and IR clears faster (Swanson et al., 2004, Archives of General Psychiatry). But calling IR "much more superior" flattens a lot of individual variability.

The Noopept critique is where things get complicated. Travis calls it an AMPA agonist and flags neurotoxicity concerns. Noopept does modulate AMPA receptors, but describing it as a direct agonist misses the nuance. Romanova et al. (2021, Neurochemical Journal) found Noopept has neuroprotective properties in some rodent models. The "anti-cognitive" claim he makes is not supported by published literature. His preference for Piracetam as a "positive allosteric modulator of AMPA" is directionally correct (Bhattacharya et al., 2001), but Piracetam's human cognitive benefit evidence is weak outside of cognitive decline populations.

What did they get wrong (or right)?

He got the adenosine mechanism for caffeine right. He got the broad dopaminergic effect of amphetamine right. Credit where it is due.

What he got wrong: Noopept is not well-characterized as neurotoxic in humans. The existing literature is mostly preclinical, and labeling it "anti-cognitive" without citation is not pharmacology, it is opinion presented as fact. Describing Adderall as part of a nootropic stack without any mention of its Schedule II status, abuse potential, or the fact that it requires a prescription and diagnosis is a significant omission. Adderall is not a supplement. Its inclusion here without those caveats is misleading to an audience that may not know the difference.

The Cerebrolysin section is nearly unintelligible in the transcript, but Cerebrolysin is a porcine-derived peptide mixture with some clinical trial data in stroke and traumatic brain injury (Guekht et al., 2017, CNS Drugs), not a proven neurogenesis tool for stimulant recovery in healthy adults. That application is speculative at best.

What should you actually know?

A few things worth separating out here. First, Adderall is a controlled substance. Using it without a prescription is illegal in the United States. Framing it as a "stimulant" on a nootropic list does not change that. If you are seeing content that treats amphetamines as lifestyle optimization tools, treat it with appropriate skepticism.

Second, the nootropic space is largely unregulated. Noopept is not FDA-approved. Cerebrolysin is not available in the US except through compounding or gray-market importation. The evidence base for most of these compounds in healthy adults is thin or nonexistent.

Third, the "sweet spot" dosing language Travis uses for Adderall ("5 to 10 milligrams") has no clinical basis as a universal recommendation. Amphetamine dosing is individualized, monitored, and titrated under medical supervision for a reason. A TikTok review is not a substitute for that.

Finally, if someone is genuinely recovering from cognitive deficits related to stimulant abuse, the evidence-based path runs through psychiatry and sleep medicine, not peptide stacks. Cerebrolysin is interesting research, but it is not a validated recovery protocol for that population.